2025/01/20 更新

写真a

コニシ ヒロアキ
小西 弘晃
KONISHI Hiroaki
所属
医学部 医学科 共同研究講座 消化器先端医学講座
外部リンク

研究キーワード

  • 分子生物学

  • 微生物学

  • 小児腫瘍学

  • 分子腫瘍学

  • 生理学

  • 薬学

  • 消化器病学

研究分野

  • ライフサイエンス / 分子生物学

  • ライフサイエンス / 腫瘍生物学

  • ライフサイエンス / 薬理学

  • ライフサイエンス / 血液、腫瘍内科学

  • ライフサイエンス / 薬系衛生、生物化学

  • ライフサイエンス / 生理学

  • ライフサイエンス / 消化器内科学

▼全件表示

学歴

  • 旭川医科大学大学院   医学系研究科   医学専攻博士課程

    2012年4月 - 2016年3月

      詳細を見る

  • 九州大学   医学系学府   医科学専攻修士課程

    2008年4月 - 2010年3月

      詳細を見る

  • 広島国際大学   薬学部   薬学科

    2004年4月 - 2008年3月

      詳細を見る

経歴

  • 旭川医科大学   消化器先端医学講座   特任講師

    2024年4月 - 現在

      詳細を見る

  • 旭川医科大学   消化器先端医学講座   特任助教

    2023年8月 - 2024年3月

      詳細を見る

  • カリフォルニア大学デービス校   小児科学講座   客員研究員

    2022年8月 - 2023年7月

      詳細を見る

  • 旭川医科大学   消化器先端医学講座   客員助教

    2022年8月 - 2023年7月

      詳細を見る

  • 旭川医科大学   消化器先端医学講座   特任助教

    2018年5月 - 2022年7月

      詳細を見る

  • 旭川医科大学   内科学講座 消化器・血液腫瘍制御内科学分野   客員助教

    2016年4月 - 2018年4月

      詳細を見る

▼全件表示

所属学協会

  • 日本薬理学会

    2020年12月 - 現在

      詳細を見る

  • 日本癌学会

    2020年4月 - 現在

      詳細を見る

  • 日本薬学会

    2020年1月 - 現在

      詳細を見る

  • 日本癌治療学会

    2019年4月 - 現在

      詳細を見る

  • 日本消化器免疫学会

    2012年3月 - 現在

      詳細を見る

留学歴

  • 2022年7月 - 2023年7月   カリフォルニア大学デービス   客員研究員

論文

  • hsa_circ_0015388 Reduces Macrophage Derived Reactive Oxygen Species in Crohn's Disease. 国際誌

    Yuya Sugiyama, Hiroaki Konishi, Tatsuya Dokoshi, Hiroki Tanaka, Yu Kobayashi, Takahiro Sasaki, Koji Yamamoto, Aki Sakatani, Keitaro Takahashi, Katsuyoshi Ando, Nobuhiro Ueno, Shin Kashima, Kentaro Moriichi, Hiroki Tanabe, Toshikatsu Okumura, Mikihiro Fujiya

    Inflammatory bowel diseases   2025年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Crohn's disease (CD) is a refractory inflammatory bowel disease with an unclear etiology. CircularRNA (circRNA) has been highlighted as a novel class of functional noncoding RNAs associated with the pathogenesis of various diseases. However, the functions of circRNA in CD remain unclear. METHODS: Biopsies were obtained from noninflammatory sites in the terminal ileum of the CD group (n = 4) and non-CD group (n = 4) and analyzed for circRNA expression using RNA sequencing. The significantly altered circRNAs were validated in the CD group (n = 45) and non-CD group (n = 15) using quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). Transcriptome analysis was conducted using circRNA-downregulated macrophage-like THP-1 cells. Reactive oxygen species (ROS) levels, cytokine mRNA expression, phagocytosis, and migration were evaluated in circRNA-downregulated THP-1 cells. RESULTS: CircularRNA sequencing analysis revealed significant differences in 31 circRNAs between the CD group and non-CD group. Quantitative reverse transcriptase-polymerase chain reaction analysis for each circRNA demonstrated significant upregulation of hsa_circ_0015388 in the CD group. Hsa_circ_0015388 was expressed in THP-1 cells, but not in HCEC-1CT and Caco-2/bbe. Transcriptome analysis in THP-1 cells transfected with scramble or hsa_circ_0015388 siRNA (small interfering RNA) showed a significant alteration in innate immune response related pathway. Reactive oxygen species production was significantly increased in the hsa_circ_0015388 downregulated THP-1 cells. Reactive oxygen species induction in the hsa_circ_0015388 knocked down THP-1 was diminished by the inhibition of TNFSF10. CONCLUSION: A comprehensive analysis of circRNA expression revealed that 31 circRNAs were dysregulated in the CD group. Hsa_circ_0015388 is expressed in macrophages and negatively regulates ROS function inhibiting the TNFSF10 pathway. This study first revealed that hsa_circ_0015388 plays a role in the pathogenesis of CD by suppressing ROS production in macrophages.

    DOI: 10.1093/ibd/izae317

    PubMed

    researchmap

  • Therapeutic efficacy of RAS inhibitor trametinib using a juvenile myelomonocytic leukemia patient-derived xenograft model. 国際誌

    Alex Q Lee, Hiroaki Konishi, Masami Ijiri, Yueju Li, Arun Panigrahi, Jeremy Chien, Noriko Satake

    Pediatric hematology and oncology   41 ( 5 )   367 - 375   2024年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Juvenile myelomonocytic leukemia (JMML) is an aggressive pediatric leukemia with few effective treatments and poor outcomes even after stem cell transplantation, the only current curative treatment. We developed a JMML patient-derived xenograft (PDX) mouse model and demonstrated the in vivo therapeutic efficacy and confirmed the target of trametinib, a RAS-RAF-MEK-ERK pathway inhibitor, in this model. A PDX model was created through transplantation of patient JMML cells into mice, up to the second generation, and successful engraftment was confirmed using flow cytometry. JMML PDX mice were treated with trametinib versus vehicle control, with a median survival of 194 days in the treatment group versus 124 days in the control group (p = 0.02). Trametinib's target as a RAS pathway inhibitor was verified by showing inhibition of ERK phosphorylation using immunoblot assays. In conclusion, trametinib monotherapy significantly prolongs survival in our JMML PDX model by inhibiting the RAS pathway. Our model can be effectively used for assessment of novel targeted treatments, including potential combination therapies, to improve JMML outcomes.

    DOI: 10.1080/08880018.2024.2343688

    PubMed

    researchmap

  • Synthesis and biological evaluation of echinomycin analogues as potential colon cancer agent. 国際誌

    Keita Kojima, Hiroaki Konishi, Kyoka Momosaki, Yuya Komatani, Akira Katsuyama, Koji Nakagawa, Kayoko Kanamitsu, Fumika Yakushiji, Mikihiro Fujiya, Satoshi Ichikawa

    Scientific reports   14 ( 1 )   7628 - 7628   2024年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer-related death, thus a novel chemotherapeutic agent for colon cancer therapy is needed. In this study, analogues of echinomycin, a cyclic peptide natural product with potent toxicity to several human cancer cell lines, were synthesized, and their biological activities against human colon cancer cells were investigated. Analogue 3 as well as 1 inhibit HIF-1α-mediated transcription. Notably, transcriptome analysis indicated that the cell cycle and its regulation were involved in the effects on cells treated with 3. Analogue 3 exhibited superior in vivo efficacy to echinomycin without significant toxicity in mouse xenograft model. The low dose of 3 needed to be efficacious in vivo is also noteworthy and our data suggest that 3 is an attractive and potentially novel agent for the treatment of colon cancer.

    DOI: 10.1038/s41598-024-58196-3

    PubMed

    researchmap

  • Probiotic-derived ferrichrome induces DDIT3-mediated antitumor effects in esophageal cancer cells. 国際誌

    Takehito Kunogi, Hiroaki Konishi, Aki Sakatani, Kentaro Moriichi, Chikage Yamamura, Koji Yamamoto, Shin Kashima, Katsuyoshi Ando, Nobuhiro Ueno, Hiroki Tanaka, Toshikatsu Okumura, Mikihiro Fujiya

    Heliyon   10 ( 6 )   e28070   2024年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Esophageal cancer, which is common among the elderly, has the poorest prognosis among gastrointestinal cancers. Previously, we demonstrated that ferrichrome, produced by the probiotic Lactobacillus casei, exhibited anti-tumor effects in various gastrointestinal cancers, including colorectal and gastric cancers, with minimal effects on non-cancerous intestinal cells. However, it remains unclear whether ferrichrome exerts anti-tumor effects in esophageal cancer. A sulforhodamine B assay revealed that ferrichrome suppressed esophageal adenocarcinoma (OE33, OE19) and squamous cell carcinoma (KYSE70) cells. Ki-67 staining indicated that ferrichrome inhibited the proliferation of esophageal cancer cells. Cell cycle analysis showed that ferrichrome inhibited the DNA synthesis. TUNEL staining revealed that ferrichrome-induced DNA fragmentation. We also confirmed the cleavage of caspase-9 and PARP in ferrichrome-treated cells. Reverse transcription polymerase chain reaction demonstrated an increase in the mRNA of DNA damage-inducible transcript 3 (DDIT-3), a key regulator of programmed cell death, in ferrichrome-treated OE33 cells. In an in vivo OE33 xenograft model, intraperitoneal administration of 5-mg/kg ferrichrome for 14 days resulted in an almost complete inhibition of tumor growth. However, 14 days of intraperitoneal administration of 20-mg/kg 5-fluorouracil (5-FU), but not 20-mg/kg ferrichrome, induced weight loss and myelosuppression in both young and aged mice. Our findings indicate that ferrichrome induces DNA damage-inducible transcript-3, thereby producing anti-tumor effects, including cell cycle arrest and apoptosis, with minimal adverse effects in esophageal cancer cells. This illustrates the high potential of ferrichrome as an anti-tumor drug against esophageal carcinoma.

    DOI: 10.1016/j.heliyon.2024.e28070

    PubMed

    researchmap

  • Cmpd10357 to treat B-cell acute lymphoblastic leukemia. 国際誌

    Alex Q Lee, Hiroaki Konishi, Elizabeth Helmke, Masami Ijiri, Jan Michael A Lerot, Emma Hicks, Jeremy R Chien, Fredric A Gorin, Noriko Satake

    Experimental hematology   119-120   8 - 13   2023年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    B-cell acute lymphoblastic leukemia (B-ALL) is the most common type of cancer found in children. Although the overall survival rates are now >80%, 15%-20% of pediatric patients relapse, with survival rates subsequently dropping to 5%-10%. Cmpd10357, 3-amino-5-arylamino-6-chloro-N- (diaminomethylene) pyrazine-2-carboximide, is a highly potent, cell-permeant compound recently shown to have cytotoxic effects on solid tumors, including human breast cancer and high-grade gliomas, independent of their proliferative status. Cmpd10357 demonstrated concentration-dependent cytotoxicity in two human B-ALL cell lines, JM1 and Reh, at half-maximal inhibitory concentrations (IC50) of 3.2 and 3.3 μM, respectively. Cmpd10357, at a dose of 5 mg/kg, significantly prolonged survival in our B-ALL xenograft mouse model, with a median survival time of 49.0 days compared with 45.5 days in the control group (p < 0.05). The cytotoxicity of Cmpd10357 demonstrated caspase-independent, nonapoptotic cancer cell demise associated with the nuclear translocation of apoptosis-inducing factor (AIF). The cytotoxicity of Cmpd10357 in B-ALL cells was inhibited by Necrostatin-1 but not by Necrosulfonamide. These studies suggest that an AIF-mediated, caspase-independent necrosis mechanism of Cmpd10357 in B-ALL could be used in combination with traditional apoptotic chemotherapeutic agents.

    DOI: 10.1016/j.exphem.2022.12.005

    PubMed

    researchmap

  • Testis-specific hnRNP is expressed in colorectal cancer cells and accelerates cell growth mediating ZDHHC11 mRNA stabilization. 国際誌

    Yuki Murakami, Hiroaki Konishi, Mikihiro Fujiya, Keitaro Takahashi, Katsuyoshi Ando, Nobuhiro Ueno, Shin Kashima, Kentaro Moriichi, Hiroki Tanabe, Toshikatsu Okumura

    Cancer medicine   11 ( 19 )   3643 - 3656   2022年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Various heterogeneous nuclear ribonucleoproteins (hnRNPs) have been reported to be associated with cancer cell growth. However, it remains unclear whether hnRNP G-T, which is specifically expressed in the testis, is expressed in tumor cells, and whether hnRNP G-T expressed in colorectal cancer (CRC) cells is associated with tumor progression. We herein report that hnRNP G-T promoted cancer cell growth and stabilized mRNA of ZDHHC11 in CRC. The cell growth was inhibited by transfection of siRNA of hnRNP G-T in cancer cells, but not in non-cancerous epithelial cells. The tumor promotive effect of hnRNP G-T was confirmed in an HCT116 transplanted mouse model. RT-PCR and western blotting indicated the augmentation of hnRNP G-T in CRC in comparison to non-cancerous cells. The downregulation of hnRNP G-T inhibited cancer cell growth and promoted apoptosis in CRC. A transcriptome analysis combined with immunoprecipitation revealed that hnRNP G-T stabilized 174 mRNAs, including ZDHHC11 mRNA. The cell growth was also suppressed by the transfection of siRNA of ZDHHC11 and the mRNA and the protein expression were decreased by the transfection of siRNA of hnRNP G-T. These results suggested that hnRNP G-T promotes the cell growth of CRC by regulating the mRNA of ZDHHC11. Therefore, hnRNP G-T will be highlighted as an effective therapeutic target with less adverse effects in CRC therapy.

    DOI: 10.1002/cam4.4738

    PubMed

    researchmap

  • Hypoxia-induced nuclear translocation of β-catenin in the healing process of frostbite. 国際誌

    Shotaro Isozaki, Hiroki Tanaka, Kie Horioka, Hiroaki Konishi, Shin Kashima, Shuhei Takauji, Mikihiro Fujiya, Henrik Druid

    Biochimica et biophysica acta. Molecular basis of disease   1868 ( 6 )   166385 - 166385   2022年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Frostbite occurs when the skin is exposed to localized low temperatures. The main causes of frostbite are thought to be direct cell injury due to freezing of cells and tissue ischemia due to abnormal blood circulation. However, the molecular mechanism of frostbite has not been elucidated. This study aims to explain the molecular dynamics of frostbite using a mouse frostbite model and keratinocyte cell culture. Comprehensive gene expression analysis performed on mouse skin samples revealed that β-catenin signaling is activated by frostbite. Immunohistochemistry showed nuclear translocation of β-catenin in the skin of frostbite model mice that was not observed in mice subjected to a mechanical skin damage model induced by tape stripping. Tissue hypoxia, as detected by pimonidazole staining, coexisted with nuclear expression of β-catenin. In keratinocyte cell cultures, nuclear translocation of β-catenin was induced by hypoxia, but not by low temperature. Hypoxia induced epithelial-mesenchymal transition - an important biological event in the healing process of skin - and in vitro wound-healing activity, both of which were suppressed by β-catenin inhibition. Our results suggest that during frostbite, impaired blood flow causes hypoxia, which in turn activates β-catenin that promotes keratinocyte motility and tissue repair.

    DOI: 10.1016/j.bbadis.2022.166385

    PubMed

    researchmap

  • Treatment of hepatocellular carcinoma with autologous platelets encapsulating sorafenib or lenvatinib: A novel therapy exploiting tumor-platelet interactions. 国際誌

    Hiroki Tanaka, Kie Horioka, Takumu Hasebe, Koji Sawada, Shunsuke Nakajima, Hiroaki Konishi, Shotaro Isozaki, Masanori Goto, Yumiko Fujii, Yuki Kamikokura, Katsuhiro Ogawa, Yuji Nishikawa

    International journal of cancer   150 ( 10 )   1640 - 1653   2022年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Hepatocellular carcinoma (HCC) activates platelets through the action of adjacent sinusoidal cells. Activated platelets bind to tumor-associated endothelial cells and release growth factors that promote tumor progression. We hypothesized that platelets encapsulated with tumor inhibitors would function as drug carriers for tumor therapy. We propose a therapeutic strategy for HCC using autologous platelets encapsulating multiple tyrosine kinase inhibitors in a rat chemically induced HCC model. Sorafenib or lenvatinib was encapsulated in platelets isolated from tumor-bearing rats in vitro. The rats were divided into groups that received repeated intravenous injections (twice a week for 10 weeks) of the following materials: placebo, sorafenib (SOR), lenvatinib (LEN), autologous platelets, autologous platelets encapsulating sorafenib (SOR-PLT) and autologous platelets encapsulating lenvatinib (LEN-PLT). The therapeutic effect was then analyzed by ultrasonography (US) and histopathological analysis. Histopathological and US analysis demonstrated extensive tumor necrosis in the tumor tissue of SOR-PLT or LEN-PLT, but not in other experimental groups. By liquid chromatography-mass spectrometry, more abundant sorafenib was detected in tumor tissues after SOR-PLT administration than in surrounding normal tissues, but no such difference in sorafenib level was observed with SOR administration. Therefore, the use of autologous platelets encapsulating drugs might be a novel therapeutic strategy for HCC.

    DOI: 10.1002/ijc.33915

    PubMed

    researchmap

  • Probiotic-derived heptelidic acid exerts antitumor effects on extraintestinal melanoma through glyceraldehyde-3-phosphate dehydrogenase activity control. 国際誌

    Shotaro Isozaki, Hiroaki Konishi, Hiroki Tanaka, Chikage Yamamura, Kentaro Moriichi, Naoki Ogawa, Mikihiro Fujiya

    BMC microbiology   22 ( 1 )   110 - 110   2022年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Several microorganisms inhabit the mammalian gastrointestinal tract and are associated with the pathogenesis of various diseases, including cancer. Recent studies have indicated that several probiotics produce antitumor molecules and inhibit host tumor progression. We demonstrated that heptelidic acid (HA), a sesquiterpene lactone derived from the probiotic Aspergillus oryzae, exerts antitumor effects against pancreatic cancer in vitro and in vivo. In this study, the antitumor effects of HA against extraintestinal melanoma were assessed in vitro and in vivo. RESULTS: Sulforhodamine B (SRB) assay revealed that the growth of B16F10 cells was significantly inhibited by HA in a concentration-dependent manner. The enzymatic activity of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) decreased in proportion with the growth inhibition effect of HA. Moreover, oral HA administration significantly suppressed the growth of transplanted B16F10 tumors without any significant changes in biochemical test values. Moreover, GAPDH activity in the transplanted tumor tissues in the HA group significantly decreased compared with that in the PBS group. CONCLUSION: This study suggests that orally administered HA was absorbed in the gastrointestinal tract, reached the cancer cells transplanted in the skin, and inhibited GAPDH activity, thereby inhibiting the growth of extraintestinal melanoma cells. Thus, this study proposes a novel system for extraintestinal tumor regulation via gut bacteria-derived bioactive mediators.

    DOI: 10.1186/s12866-022-02530-0

    PubMed

    researchmap

  • Mutant GNAS limits tumor aggressiveness in established pancreatic cancer via antagonizing the KRAS-pathway.

    Hidemasa Kawabata, Yusuke Ono, Nobue Tamamura, Kyohei Oyama, Jun Ueda, Hiroki Sato, Kenji Takahashi, Kenzui Taniue, Tetsuhiro Okada, Syugo Fujibayashi, Akihiro Hayashi, Takuma Goto, Katsuro Enomoto, Hiroaki Konishi, Mikihiro Fujiya, Keita Miyakawa, Mishie Tanino, Yuji Nishikawa, Daisuke Koga, Tsuyoshi Watanabe, Chiho Maeda, Hidenori Karasaki, Andrew S Liss, Yusuke Mizukami, Toshikatsu Okumura

    Journal of gastroenterology   57 ( 3 )   208 - 220   2022年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Mutations in GNAS drive pancreatic tumorigenesis and frequently occur in intraductal papillary mucinous neoplasm (IPMN); however, their value as a therapeutic target is yet to be determined. This study aimed at evaluating the involvement of mutant GNAS in tumor aggressiveness in established pancreatic cancer. METHODS: CRISPR/Cas9-mediated GNAS R201H silencing was performed using human primary IPMN-associated pancreatic cancer cells. The role of oncogenic GNAS in tumor maintenance was evaluated by conducting cell culture and xenograft experiments, and western blotting and transcriptome analyses were performed to uncover GNAS-driven signatures. RESULTS: Xenografts of GNAS wild-type cells were characterized by a higher Ki-67 labeling index relative to GNAS-mutant cells. Phenotypic alterations in the GNAS wild-type tumors resulted in a significant reduction in mucin production accompanied by solid with massive stromal components. Transcriptional profiling suggested an apparent conflict of mutant GNAS with KRAS signaling. A significantly higher Notch intercellular domain (NICD) was observed in the nuclear fraction of GNAS wild-type cells. Meanwhile, inhibition of protein kinase A (PKA) induced NICD in GNAS-mutant IPMN cells, suggesting that NOTCH signaling is negatively regulated by the GNAS-PKA pathway. GNAS wild-type cells were characterized by a significant invasive property relative to GNAS-mutant cells, which was mediated through the NOTCH regulatory pathway. CONCLUSIONS: Oncogenic GNAS induces mucin production, not only via MUC2 but also via MUC5AC/B, which may enlarge cystic lesions in the pancreas. The mutation may also limit tumor aggressiveness by attenuating NOTCH signaling; therefore, such tumor-suppressing effects must be considered when therapeutically inhibiting the GNAS pathway.

    DOI: 10.1007/s00535-021-01846-4

    PubMed

    researchmap

  • Soluble thrombomodulin ameliorates aberrant hemostasis after rewarming in a rat accidental hypothermia model. 国際誌

    Shuhei Takauji, Hiroki Tanaka, Mineji Hayakawa, Kie Horioka, Shotaro Isozaki, Hiroaki Konishi

    Biochemical and biophysical research communications   587   1 - 8   2022年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Accidental hypothermia (AH) sometimes leads to coagulation disorder, especially in severe AH. We previously demonstrated that intrasplenic platelet activation caused aberrant hemostasis and thrombus formation after rewarming in a murine AH model. However, no study has focused on the appropriate management of platelets causing coagulation activation after rewarming of AH. We investigated whether or not recombinant soluble thrombomodulin (rTM) can suppress thrombosis formation after rewarming using a rat AH model. METHODS: Wistar rats were exposed to an ambient temperature of -20 °C under general anesthesia until their rectal temperature decreased to 26 °C. The Hypo group rats (n = 5) were immediately euthanized, while the Hypo/Re group (n = 5) and rTM group rats (n = 5), which were administered rTM (1 mg/kg) via the tail vein, were rewarmed until the rectal temperature returned to 34 °C and then euthanized 6 h later. Tissue and blood samples were collected from all rats for histopathological and coagulation analyses at euthanasia. RESULTS: There was no significant change in the D-dimer level in the Hypo group rats, while the D-dimer level was significantly elevated at 6 h after rewarming in the Hypo/Re group rats (P = 0.015), and histopathology detected both fibrin and platelets in the renal glomerulus. However, the rTM group rats did not show any elevation of the D-dimer levels at 6 h after rewarming, and no fibrin was noted on histopathology. CONCLUSIONS: rTM may be useful as an appropriate anticoagulant in cases of aberrant hemostasis after rewarming of AH.

    DOI: 10.1016/j.bbrc.2021.11.086

    PubMed

    researchmap

  • A distinct subpopulation of leukemia initiating cells in acute precursor B lymphoblastic leukemia: quiescent phenotype and unique transcriptomic profile. 国際誌

    Alex Q Lee, Hiroaki Konishi, Connie Duong, Sakiko Yoshida, Ryan R Davis, Jonathan E Van Dyke, Masami Ijiri, Bridget McLaughlin, Kyoungmi Kim, Yueju Li, Laurel Beckett, Nitin Nitin, John D McPherson, Clifford G Tepper, Noriko Satake

    Frontiers in oncology   12   972323 - 972323   2022年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    In leukemia, a distinct subpopulation of cancer-initiating cells called leukemia stem cells (LSCs) is believed to drive population expansion and tumor growth. Failing to eliminate LSCs may result in disease relapse regardless of the amount of non-LSCs destroyed. The first step in targeting and eliminating LSCs is to identify and characterize them. Acute precursor B lymphoblastic leukemia (B-ALL) cells derived from patients were incubated with fluorescent glucose analog 2-(N-(7-Nitrobenz-2-oxa-1, 3-diazol-4-yl) Amino)-2-Deoxyglucose (NBDG) and sorted based on NBDG uptake. Cell subpopulations defined by glucose uptake were then serially transplanted into mice and evaluated for leukemia initiating capacity. Gene expression profiles of these cells were characterized using RNA-Sequencing (RNA-Seq). A distinct population of NBDG-low cells was identified in patient B-ALL samples. These cells are a small population (1.92% of the entire leukemia population), have lower HLA expression, and are smaller in size (4.0 to 7.0 μm) than the rest of the leukemia population. All mice transplanted with NBDG-low cells developed leukemia between 5 and 14 weeks, while those transplanted with NBDG-high cells did not develop leukemia (p ≤ 0.0001-0.002). Serial transplantation of the NBDG-low mouse model resulted in successful leukemia development. NBDG-medium (NBDG-med) populations also developed leukemia. Interestingly, comprehensive molecular characterization of NBDG-low and NBDG-med cells from patient-derived xenograft (PDX) models using RNA-Seq revealed a distinct profile of 2,162 differentially-expressed transcripts (DETs) (p<0.05) with 70.6% down-regulated in NBDG-low cells. Hierarchical clustering of DETs showed distinct segregation of NBDG-low from NBDG-med and NBDG-high groups with marked transcription expression alterations in the NBDG-low group consistent with cancer survival. In conclusion, A unique subpopulation of cells with low glucose uptake (NBDG-low) in B-ALL was discovered. These cells, despite their quiescence characteristics, once transplanted in mice, showed potent leukemia initiating capacity. Although NBDG-med cells also initiated leukemia, gene expression profiling revealed a distinct signature that clearly distinguishes NBDG-low cells from NBDG-med and the rest of the leukemia populations. These results suggest that NBDG-low cells may represent quiescent LSCs. These cells can be activated in the appropriate environment in vivo, showing leukemia initiating capacity. Our study provides insight into the biologic mechanisms of B-ALL initiation and survival.

    DOI: 10.3389/fonc.2022.972323

    PubMed

    researchmap

  • Tumor-Progressive Mechanisms Mediating miRNA-Protein Interaction. 国際誌

    Hiroaki Konishi, Hiroki Sato, Kenji Takahashi, Mikihiro Fujiya

    International journal of molecular sciences   22 ( 22 )   2021年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    MicroRNAs (miRNAs) are single-stranded short-chain RNAs that are endogenously expressed in vertebrates; they are considered the fine-tuners of cellular protein expression that act by modifying mRNA translation. miRNAs control tissue development and differentiation, cell growth, and apoptosis in cancer and non-cancer cells. Aberrant regulation of miRNAs is involved in the pathogenesis of various diseases including cancer. Numerous investigations have shown that the changes in cellular miRNA expression in cancerous tissues and extracellular miRNAs enclosed in exosomes are correlated with cancer prognosis. Therefore, miRNAs can be used as cancer biomarkers and therapeutic targets for cancer in clinical applications. In the previous decade, miRNAs have been shown to regulate cellular functions by directly binding to proteins and mRNAs, thereby controlling cancer progression. This regulatory system implies that cancer-associated miRNAs can be applied as molecular-targeted therapy. This review discusses the roles of miRNA-protein systems in cancer progression and its future applications in cancer treatment.

    DOI: 10.3390/ijms222212303

    PubMed

    researchmap

  • Polyphosphate, Derived from Lactobacillus brevis, Modulates the Intestinal Microbiome and Attenuates Acute Pancreatitis. 国際誌

    Shuhei Takauji, Hiroaki Konishi, Mikihiro Fujiya, Nobuhiro Ueno, Hiroki Tanaka, Hiroki Sato, Shotaro Isozaki, Shin Kashima, Kentaro Moriichi, Yusuke Mizukami, Toshikatsu Okumura

    Digestive diseases and sciences   66 ( 11 )   3872 - 3884   2021年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: We previously showed that Lactobacillus brevis-derived polyphosphate (poly P) exerts a curative effect on intestinal inflammation. However, whether or not poly P improves the inflammation and injury of distant organs remains unclear. AIMS: We aimed to investigate the change in the intestinal microbiome and to evaluate the protective effect of poly P on injuries in a cerulein-induced acute pancreatitis (AP) mouse. METHODS: Poly P was orally administered to BALB/C mice every day for 24 days, and then mice were intraperitoneally injected with cerulein. Before cerulein injection, stool samples were collected and analyzed by 16S rRNA gene sequencing. Mice were sacrificed at 24 h after the last cerulein injection; subsequently, the serum, pancreas, and colon were collected. RESULTS: The microbial profile differed markedly between poly P and control group. Notably, the levels of beneficial bacteria, including Alistipes and Candidatus_Saccharimonas, were significantly increased, while those of the virulent bacteria Desulfovibrio were decreased in the poly P group. The elevations of the serum amylase and lipase levels by cerulein treatment were suppressed by the pre-administration of poly P for 24 days, but not for 7 days. The numbers of cells MPO-positive by immunohistology were decreased and the levels of MCP-1 significantly reduced in the AP + Poly P group. An immunofluorescence analysis showed that the ZO-1 and occludin in the colon was strongly augmented in the epithelial cell membrane layer in the AP + Poly P group. CONCLUSIONS: Poly P attenuates AP through both modification of the intestinal microbiome and enhancement of the intestinal barrier integrity.

    DOI: 10.1007/s10620-020-06747-9

    PubMed

    researchmap

  • The Identification of RNA-Binding Proteins Functionally Associated with Tumor Progression in Gastrointestinal Cancer. 国際誌

    Hiroaki Konishi, Shin Kashima, Takuma Goto, Katsuyoshi Ando, Aki Sakatani, Hiroki Tanaka, Nobuhiro Ueno, Kentaro Moriichi, Toshikatsu Okumura, Mikihiro Fujiya

    Cancers   13 ( 13 )   2021年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Previous investigations have indicated that RNA-binding proteins (RBPs) are key molecules for the development of organs, differentiation, cell growth and apoptosis in cancer cells as well as normal cells. A bioinformatics analysis based on the mRNA expression and a somatic mutational database revealed the association between aberrant expression/mutations of RBPs and cancer progression. However, this method failed to detect functional alterations in RBPs without changes in the expression, thus leading to false negatives. To identify major tumor-associated RBPs, we constructed an siRNA library based on the database of RBPs and assessed the influence on the growth of colorectal, pancreatic and esophageal cancer cells. A comprehensive analysis of siRNA functional screening findings using 1198 siRNAs targeting 416 RBPs identified 41 RBPs in which 50% inhibition of cell growth was observed in cancer cells. Among these RBPs, 12 showed no change in the mRNA expression and no growth suppression in non-cancerous cells when downregulated by specific siRNAs. We herein report for the first time cancer-promotive RBPs identified by a novel functional assessment using an siRNA library of RBPs combined with expressional and mutational analyses.

    DOI: 10.3390/cancers13133165

    PubMed

    researchmap

  • Probiotic Aspergillus oryzae produces anti-tumor mediator and exerts anti-tumor effects in pancreatic cancer through the p38 MAPK signaling pathway. 国際誌

    Hiroaki Konishi, Shotaro Isozaki, Shin Kashima, Kentaro Moriichi, Satoshi Ichikawa, Kazuki Yamamoto, Chikage Yamamura, Katsuyoshi Ando, Nobuhiro Ueno, Hiroaki Akutsu, Naoki Ogawa, Mikihiro Fujiya

    Scientific reports   11 ( 1 )   11070 - 11070   2021年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Intake of probiotics or fermented food produced by some probiotic bacteria is believed to exert anti-tumor functions in various cancers, including pancreatic cancer, because several studies have demonstrated the anti-tumor effects of probiotic bacteria in vitro and in vivo in animal carcinogenesis models. However, the mechanisms underlying the anticancer effects of probiotics on pancreatic cancer have not been clarified. In this study, we assessed the anti-tumor effects of probiotic bacteria against pancreatic cancer cells. Among the known probiotic bacteria, Aspergillus oryzae exhibited a strong pancreatic tumor suppression effect. The culture supernatant of A. oryzae was separated by HPLC. Heptelidic acid was identified as an anti-tumor molecule derived from A. oryzae by LC-MS and NMR analysis. The anti-tumor effect of heptelidic acid was exhibited in vitro and in vivo in a xenograft model of pancreatic cancer cells. The anti-tumor effect of heptelidic acid was exerted by the p38 MAPK signaling pathway. Heptelidic acid traverses the intestinal mucosa and exerts anti-tumor effects on pancreatic cancer cells. This is a novel anti-tumor mechanism induced by beneficial bacteria against pancreatic cancer in which bacterial molecules pass through the intestinal tract, reach the extra-intestinal organs, and then induce apoptosis via an inducible signaling pathway.

    DOI: 10.1038/s41598-021-90707-4

    PubMed

    researchmap

  • Bacteria-derived ferrichrome inhibits tumor progression in sporadic colorectal neoplasms and colitis-associated cancer. 国際誌

    Takuya Iwama, Mikihiro Fujiya, Hiroaki Konishi, Hiroki Tanaka, Yuki Murakami, Takehito Kunogi, Takahiro Sasaki, Keitaro Takahashi, Katsuyoshi Ando, Nobuhiro Ueno, Shin Kashima, Kentaro Moriichi, Hiroki Tanabe, Toshikatsu Okumura

    Cancer cell international   21 ( 1 )   21 - 21   2021年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Colorectal cancers develop through several pathways, including the adenoma-carcinoma sequence and colitis-associated carcinogenesis. An altered intestinal microflora has been reported to be associated with the development and progression of colorectal cancer via these pathways. We identified Lactobacillus casei-derived ferrichrome as a mediator of the bacterial anti-tumor effect of colorectal cancer cells through the upregulation of DDIT3. In this study, we investigated the anti-tumor effects of ferrichrome on precancerous conditions and cancer cells associated with sporadic as well as colitis-associated colorectal cancer. METHODS: SRB and MTT assays were performed to assess growth inhibition in vitro. Eighteen organoids were prepared from biopsy specimens obtained by colonoscopy. An AOM-DSS carcinogenesis model and xenograft model of colorectal cancer cells were generated for the assessment of the tumor suppressive effect of ferrichrome in vivo. RESULTS: Ferrichrome inhibited the cell growth of colorectal cancer cells in vitro and in in vivo xenograft models. Ferrichrome exerted a strong tumor-suppressive effect that was superior to that of currently available anti-tumor agents, including 5-FU and cisplatin, both in vitro and in vivo. The tumor-suppressive effect of the combination of ferrichrome and 5-FU was superior to that of single treatment with either drug. The tumor suppressive effects of ferrichrome were confirmed through the upregulation of DDIT3 in patient-derived organoids of adenoma and carcinoma. Ferrichrome inhibited the tumor progression in the AOM-DSS model while exhibiting no anti-inflammatory effect in the DSS-colitis model, suggesting that ferrichrome inhibited cancer cells, but not a precancerous condition, via the colitis-associated pathway. CONCLUSIONS: Ferrichrome exerts a tumor suppressive effect on precancerous conditions and cancer cells associated with sporadic as well as colitis-associated colorectal cancer. The anti-tumor effect of ferrichrome was mediated by the upregulation of DDIT3, and was superior to that of 5-FU or cisplatin. These results suggest that Lactobacillus brevis-derived ferrichrome may be a candidate anti-tumor drug for the treatment of colorectal neoplasms.

    DOI: 10.1186/s12935-020-01723-9

    PubMed

    researchmap

  • Probiotic-Derived Polyphosphate Accelerates Intestinal Epithelia Wound Healing through Inducing Platelet-Derived Mediators. 国際誌

    Shotaro Isozaki, Hiroaki Konishi, Mikihiro Fujiya, Hiroki Tanaka, Yuki Murakami, Shin Kashima, Katsuyoshi Ando, Nobuhiro Ueno, Kentaro Moriichi, Toshikatsu Okumura

    Mediators of inflammation   2021   5582943 - 5582943   2021年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Inflammatory bowel disease (IBD), such as ulcerative colitis (UC) and Crohn's disease (CD), is an intractable intestinal inflammation associated with the disruption of the intestinal mucosa. We previously demonstrated that Lactobacillus brevis-derived long-chain polyphosphate (poly P) improved the intestinal barrier function by the upregulation of cell adhesion and relieved intestinal inflammation, thereby exerting a curing effect on colitis in vitro, in vivo, and in an investigator-initiated clinical study of UC. However, how poly P improves mucosal defects induced by intestinal inflammation has not been elucidated. In this study, we detected the accumulation of platelets in inflamed tissues induced by poly P in a dextran sulfate sodium- (DSS-) induced colitis mouse model. A light transmission aggregometry analysis and scanning electron microscopy showed that poly P promoted the platelet aggregation. An SRB assay and ki-67 staining showed that the supernatant of poly P-treated platelet-rich plasma (PRP) increased intestinal epithelial cell growth. A wound healing assay showed that the supernatant of poly P-treated PRP, but not poly P itself, accelerated wound healing. A Western blotting analysis indicated that mitogen-activated protein kinase activation was induced by the supernatant of poly P-treated human PRP in the epithelial cells and its wound healing effect was significantly decreased by the inhibition of ERK signaling. These data suggested that platelet-derived mediators induced by poly P improved intestinal inflammation through the promotion of epithelial cell growth by the activation of the ERK signaling pathway. The mechanism is a novel host-microbe interaction through mammalian platelet-derived mediators induced by bacterial molecules.

    DOI: 10.1155/2021/5582943

    PubMed

    researchmap

  • The Optimal Dose of Tacrolimus in Combination Therapy with an Anti-TNFα Antibody in a Mouse Colitis Model.

    Yuki Murakami, Mikihiro Fujiya, Hiroaki Konishi, Shotaro Isozaki, Yuya Sugiyama, Yu Kobayashi, Takahiro Sasaki, Takehito Kunogi, Keitaro Takahashi, Katsuyoshi Ando, Nobuhiro Ueno, Shin Kashima, Kentaro Moriichi, Hiroki Tanabe, Toshikatsu Okumura

    Biological & pharmaceutical bulletin   44 ( 4 )   564 - 570   2021年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    An attempt to use combination therapy with anti-tumor necrosis factor α (TNFα) antibodies and tacrolimus (TAC) has been tried to induce remission in ulcerative colitis (UC). However, the optimal dose of TAC in combination therapy with anti-TNFα antibodies (TAC + anti-TNFα therapy) remains unclear. We examined the efficacy of various doses of TAC + anti-TNFα therapy in a mouse colitis model. Dextran sulfate sodium induced colitis model mice were divided into an anti-TNFα antibody monotherapy group and the groups that received various doses of TAC + anti-TNFα therapy. The nuclear factor expression of activated T-cells, cytoplasmic 1 (NFATc1) in the nuclei and the mRNA expression of inflammatory cytokines were assessed by immunohistochemistry and RT-PCR, respectively. The serum anti-TNFα antibody concentration was measured with an enzyme-linked immunosorbent assay. The colon length and histological severity were significantly improved in the groups that received any dose of TAC + anti-TNFα therapy. The nuclear expression of NFATc1 was inversely proportional to the administered doses of TAC. The expression levels of inflammatory cytokines tended to decrease in proportion to the dose of TAC. The serum concentration of anti-TNFα antibodies in the high-dose TAC + anti-TNFα therapy was significantly higher than those in the other groups. Low-dose TAC exerted its immunosuppressive effect on T-cells, and additionally, high-dose TAC maintained the serum anti-TNFα antibody concentration. When administered in combination with anti-TNFα antibodies, the dose of TAC should be adjusted according to the disease severity.

    DOI: 10.1248/bpb.b20-00916

    PubMed

    researchmap

  • Rewarming from accidental hypothermia enhances whole blood clotting properties in a murine model. 国際誌

    Kie Horioka, Hiroki Tanaka, Shotaro Isozaki, Hiroaki Konishi, Lynda Addo, Shuhei Takauji, Henrik Druid

    Thrombosis research   195   114 - 119   2020年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Hypothermia triggers coagulation, which can lead to the development of a life-threatening condition. We previously reported that hypothermia induces platelet activation in the spleen, resulting in microthrombosis after rewarming. However, the changes in whole blood clotting properties that occur remain unclear. Using thromboelastography, we investigated blood clotting activity and the effects of rewarming in a murine model of hypothermia. METHODS: C57Bl/6 mice were exposed to an ambient temperature of -20 °C under general anesthesia until their rectal temperature decreased to 15 °C. One group of mice was kept at 4 °C for 2 h and then euthanized. Another group was rewarmed, kept in normal conditions for 24 h, and then euthanized. Tissue and citrated whole blood samples were obtained from the mice for histopathological analysis, flow cytometry, and thromboelastography. RESULTS: Hypothermia induced the activation of platelets in the spleen; however, rewarming significantly reduced the number of activated platelets in the spleen while their numbers significantly increased in peripheral blood. In hypothermic mice not subjected to rewarming, no increase in activated platelets was observed in peripheral blood. Thromboelastography analysis showed that whole blood samples from the rewarmed mice displayed an enhanced clotting strength. CONCLUSIONS: Rewarming from hypothermia enhances whole blood coagulation activity accompanied by an increase in the number of active platelets in peripheral blood. This phenomenon may lead to formation of microthrombi and thrombotic disorders.

    DOI: 10.1016/j.thromres.2020.07.022

    PubMed

    researchmap

  • Probiotic‑derived ferrichrome inhibits the growth of refractory pancreatic cancer cells. 国際誌

    Akemi Kita, Mikihiro Fujiya, Hiroaki Konishi, Hiroki Tanaka, Shin Kashima, Takuya Iwama, Masami Ijiri, Yuki Murakami, Shuhei Takauji, Takuma Goto, Aki Sakatani, Katsuyoshi Ando, Nobuhiro Ueno, Naoki Ogawa, Toshikatsu Okumura

    International journal of oncology   57 ( 3 )   721 - 732   2020年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Pancreatic cancer is associated with a poor prognosis due to challenges in early detection, severe progression of the primary tumor, metastatic lesions, and resistance to antitumor agents. However, previous studies have indicated a relationship between the microbiome and pancreatic cancer outcomes. Our previous study demonstrated that ferrichrome derived from Lactobacillus casei, a probiotic bacteria, exhibited tumor‑suppressive effects in colorectal and gastric cancer, and that the suppressive effects were stronger than conventional antitumor agents, such as 5‑fluorouracil (5‑FU) and cisplatin, suggesting that certain probiotics exert antitumorigenic effects. However, whether or not probiotic‑derived molecules, including ferrichrome, exert a tumor‑suppressive effect in other gastrointestinal tumors, such as pancreatic cancer, remains unclear. In the present study, it was demonstrated that probiotic‑derived ferrichrome inhibited the growth of pancreatic cancer cells, and its tumor‑suppressive effects were further revealed in 5‑FU‑resistant pancreatic cancer cells in vitro and in vivo in a mouse xenograft model. Ferrichrome inhibited the progression of cancer cells via dysregulation of the cell cycle by activating p53. DNA fragmentation and cleavage of poly (ADP‑ribose) polymerase were induced by ferrichrome treatment, suggesting that ferrichrome induced apoptosis in pancreatic cancer cells. A transcriptome analysis revealed that the expression p53‑associated mRNAs was significantly altered by ferrichrome treatment. Thus, the tumor‑suppressive effects of probiotics may mediated by probiotic‑derived molecules, such as ferrichrome, which may have applications as an antitumor drug, even in refractory and 5‑FU‑resistant pancreatic cancer.

    DOI: 10.3892/ijo.2020.5096

    PubMed

    researchmap

  • Heterogenous Nuclear Ribonucleoprotein H1 Promotes Colorectal Cancer Progression through the Stabilization of mRNA of Sphingosine-1-Phosphate Lyase 1. 国際誌

    Keitaro Takahashi, Mikihiro Fujiya, Hiroaki Konishi, Yuki Murakami, Takuya Iwama, Takahiro Sasaki, Takehito Kunogi, Aki Sakatani, Katsuyoshi Ando, Nobuhiro Ueno, Shin Kashima, Kentaro Moriichi, Hiroki Tanabe, Toshikatsu Okumura

    International journal of molecular sciences   21 ( 12 )   2020年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The oncogenic properties of heterogeneous nuclear ribonucleoprotein H1 (hnRNP H1) have been reported, although the tumor-promoting mechanism remains unclear. We herein report the mechanism underlying colorectal cancer cell progression mediated by hnRNP H1. The growth of colorectal cancer cells was suppressed by hnRNP H1 downregulation. A terminal deoxynucleotidyl transferase dUTP nick-end labeling assay revealed the anti-apoptotic effect of hnRNP H1 in colorectal cancer cells. An RNA immunoprecipitation assay revealed that hnRNP H1 bound to sphingosine-1-phosphate lyase 1 (SGPL1). Reverse transcription-polymerase chain reaction revealed the high expression of hnRNP H1 mRNA in colorectal cancer cells and Spearman's rank correlation coefficient showed a strong positive correlation between hnRNP H1 mRNA and SGPL1 mRNA. An siRNA of hnRNP H1 decreased SGPL1 mRNA expression in colorectal cancer cells, but not in non-tumorous cells. These findings suggested that hnRNP H1 increased SGPL1 mRNA expression specifically in cancer cells through direct binding. Targeted knockdown of hnRNP H1 or SGPL1 with siRNAs upregulated p53 phosphorylation and p53-associated molecules, resulting in cell growth inhibition, while hnRNP H1 upregulated the mRNA of SGPL1 and inhibited p53 activation, thereby promoting tumor cell growth. This is a novel mechanism underlying colorectal cancer cell progression mediated by hnRNP H1-SGPL1 mRNA stabilization.

    DOI: 10.3390/ijms21124514

    PubMed

    researchmap

  • Low temperature induces von-willebrand factor expression via increased early growth response 1 transcriptional activity in splenic sinusoidal endothelial cells. 国際誌

    Kie Horioka, Hiroki Tanaka, Shotaro Isozaki, Hiroaki Konishi, Lynda Addo, Shuhei Takauji, Henrik Druid

    Biochemical and biophysical research communications   526 ( 1 )   239 - 245   2020年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    von Willebrand factor (vWF) is a large plasma glycoprotein that plays an important role in hemostasis by forming molecular bridges with platelets following vascular injury. Previously, we reported that hypothermia enhanced vWF production in the spleen, which resulted in the activation of the platelet pool in a hypothermia-induced murine model. However, the mechanisms that regulate vWF expression under hypothermic conditions remain unclear. In this study, we focused on vWF expression under hypothermic conditions in splenic endothelial cell culture. Human splenic endothelial cells (HSEC) were incubated at 20 °C for 1 h. Total RNA was extracted from the cells, and cDNA microarray gene expression analysis was performed. Genes that may be associated with vWF expression in low temperature culture conditions were then selected for further analysis. Gene expression analysis showed that low temperature conditions increased the expression of FOS and EGR1. We then hypothesized that these factors upregulate vWF mRNA expression in HSEC. The transcriptional inhibitors of EGR1 significantly inhibited vWF mRNA expression in HSEC cultured at a low temperature. Our analysis revealed that low temperatures enhance the gene expression of EGR1, which transcriptionally increases vWF expression. This acute-phase reaction may play an important role in platelet activation in the spleen during hypothermia.

    DOI: 10.1016/j.bbrc.2020.03.073

    PubMed

    researchmap

  • A tumor-specific modulation of heterogeneous ribonucleoprotein A0 promotes excessive mitosis and growth in colorectal cancer cells. 国際誌

    Hiroaki Konishi, Mikihiro Fujiya, Shin Kashima, Aki Sakatani, Tatsuya Dokoshi, Katsuyoshi Ando, Nobuhiro Ueno, Takuya Iwama, Kentaro Moriichi, Hiroki Tanaka, Toshikatsu Okumura

    Cell death & disease   11 ( 4 )   245 - 245   2020年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    RNA regulation mediating RNA-binding proteins (RBPs) have been shown to be related to the maintenance of homeostasis as well as cancer progression. However, the tumor-associated functions as well as the detailed mechanisms underlying the anti-tumor effects of most RBPs have yet to be explored. We herein report that the phosphorylated heterogeneous ribonucleoprotein (hnRNP) A0 promotes mitosis through the RAS-associated protein 3 GTPase-activating protein catalytic subunit 1 (RAB3GAP1)-Zeste white 10 interactor (ZWINT1) cascade. The downregulation assay of 20 representative hnRNPs, a major family of RNA-binding proteins, in colorectal cancer cells revealed that hnRNPA0 is a strong regulator of cancer cell growth. The tumor promotive function of hnRNPA0 was confirmed in gastrointestinal cancer cells, including pancreatic, esophageal, and gastric cancer cells, but not in non-cancerous cells. Flow cytometry and Western blotting analyses revealed that hnRNPA0 inhibited the apoptosis through the maintenance of G2/M phase promotion in colorectal cancer cells. A comprehensive analysis of mRNAs regulated by hnRNP A0 and immunostaining revealed that mitotic events were regulated by the hnRNPA0-RAB3GAP1 mRNA-mediated ZWINT-1 stabilization in colorectal cancer cells, but not in non-tumorous cells. The interaction of hnRNP A0 with mRNAs was dramatically changed by the deactivation of its phosphorylation site in cancer cells, but not in non-tumorous cells. Therefore, the tumor-specific biological functions characterized by the abnormal phosphorylation of RBPs are considered to be an attractive target for tumor treatment.

    DOI: 10.1038/s41419-020-2439-7

    PubMed

    researchmap

  • Long-Chain Polyphosphate Is a Potential Agent for Inducing Mucosal Healing of the Colon in Ulcerative Colitis. 国際誌

    Mikihiro Fujiya, Nobuhiro Ueno, Shin Kashima, Kazuyuki Tanaka, Aki Sakatani, Katsuyoshi Ando, Kentaro Moriichi, Hiroaki Konishi, Naoya Kamiyama, Yoshikazu Tasaki, Tomohiro Omura, Kazuo Matsubara, Masaki Taruishi, Toshikatsu Okumura

    Clinical pharmacology and therapeutics   107 ( 2 )   452 - 461   2020年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The goal of ulcerative colitis (UC) treatment has recently been shown to be "mucosal healing," as no drug directly induces mucosal healing. Probiotics possess sufficient safety, but their efficacy in the treatment of UC remains controversial because of the influence of intestinal conditions. It is believed that the identification of bioactive molecules produced by probiotics and their application will help to solve this issue. We therefore identified a probiotic-derived long-chain polyphosphate as a molecule enhancing the intestinal barrier function. This study demonstrated that long-chain polyphosphate exhibited antiinflammatory effects in a human macrophage and interleukin-10 knockout transfusion mouse model. The first-in-human trial showed that 7 of the 10 enrolled patients acquired clinical remission, 4 of whom achieved endoscopic remission despite a history of treatment with anti-tumor necrosis factor (TNF)-α agents. No adverse reactions were observed. Long-chain polyphosphate might be useful for the treatment of refractory UC, even in patients with failure or intolerance to anti-TNF-α therapy.

    DOI: 10.1002/cpt.1628

    PubMed

    researchmap

  • Acute Colchicine Poisoning Causes Endotoxemia via the Destruction of Intestinal Barrier Function: The Curative Effect of Endotoxin Prevention in a Murine Model. 国際誌

    Kie Horioka, Hiroki Tanaka, Shotaro Isozaki, Hiroaki Konishi, Mikihiro Fujiya, Katsuhiro Okuda, Masaru Asari, Hiroshi Shiono, Katsuhiro Ogawa, Keiko Shimizu

    Digestive diseases and sciences   65 ( 1 )   132 - 140   2020年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Colchicine binds to intracellular tubulin and prevents mitosis. Colchicine is also used as an anti-inflammatory drug. Meanwhile, excess administration of medication or accidental ingestion of colchicine-containing plants can cause acute colchicine poisoning, which initially results in gastrointestinal effects that may be followed by multiorgan dysfunction. However, the mechanism of colchicine poisoning remains unclear, and there are no standard therapeutic strategies. AIMS: We focused on intestinal barrier function and attempted to reveal the underlying mechanism of colchicine poisoning using an animal model. METHODS: Colchicine was orally administered to C57Bl/6 mice. Then, we performed histopathological analysis, serum endotoxin assays, and intestinal permeability testing. Additionally, the LPS-TLR4 signaling inhibitor TAK-242 was intraperitoneally injected after colchicine administration to analyze the therapeutic effect. RESULTS: We observed villus height reduction and increased numbers of apoptotic cells in the gastrointestinal epithelium of colchicine-treated mice. Both intestinal permeability and serum endotoxin levels were higher in colchicine-treated mice than in control mice. Although colchicine-poisoned mice died within 25 h, those that also received TAK-242 treatment survived for more than 48 h. CONCLUSION: Colchicine disrupted intestinal barrier function and caused endotoxin shock. Therapeutic inhibition of LPS-TLR4 signaling might be beneficial for treating acute colchicine poisoning.

    DOI: 10.1007/s10620-019-05729-w

    PubMed

    researchmap

  • An elevated expression of serum exosomal microRNA-191, - 21, -451a of pancreatic neoplasm is considered to be efficient diagnostic marker. 国際誌

    Takuma Goto, Mikihiro Fujiya, Hiroaki Konishi, Junpei Sasajima, Shugo Fujibayashi, Akihiro Hayashi, Tatsuya Utsumi, Hiroki Sato, Takuya Iwama, Masami Ijiri, Aki Sakatani, Kazuyuki Tanaka, Yoshiki Nomura, Nobuhiro Ueno, Shin Kashima, Kentaro Moriichi, Yusuke Mizukami, Yutaka Kohgo, Toshikatsu Okumura

    BMC cancer   18 ( 1 )   116 - 116   2018年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Pancreatic cancer is associated with an extremely poor prognosis, so new biomarkers that can detect the initial stages are urgently needed. The significance of serum microRNA (miR) levels in pancreatic neoplasm such as pancreatic cancer and intraductal papillary mucinous neoplasm (IPMN) diagnosis remains unclear. We herein evaluated the usefulness of miRs enclosed in serum exosomes (ExmiRs) as diagnostic markers. METHODS: The ExmiRs from patients with pancreatic cancer (n = 32) or IPMN (n = 29), and patients without neoplasms (controls; n = 22) were enriched using ExoQuick-TC™. The expression of ExmiRs was evaluated using a next-generation sequencing analysis, and the selected three miRs through this analysis were confirmed by a quantitative real-time polymerase chain reaction. RESULTS: The expression of ExmiR-191, ExmiR-21 and ExmiR-451a was significantly up-regulated in patients with pancreatic cancer and IPMN compared to the controls (p < 0.05). A receiver operating characteristic curve analysis showed that the area under the curve and the diagnostic accuracy of ExmiRs were 5-20% superior to those of three serum bulky circulating miRs (e.g.; ExmiR-21: AUC 0.826, accuracy 80.8%. Circulating miR-21: AUC 0.653, accuracy 62.3%). In addition, high ExmiR-451a was associated with mural nodules in IPMN (p = 0.010), and high ExmiR-21 was identified as a candidate prognostic factor for the overall survival (p = 0.011, HR 4.071, median OS of high-ExmiR-21: 344 days, median OS of low-ExmiR-21: 846 days) and chemo-resistant markers (p = 0.022). CONCLUSIONS: The level of three ExmiRs can thus serve as early diagnostic and progression markers of pancreatic cancer and IPMN, and considered more useful markers than the circulating miRs (limited to these three miRs).

    DOI: 10.1186/s12885-018-4006-5

    PubMed

    researchmap

  • Ferrichrome identified from Lactobacillus casei ATCC334 induces apoptosis through its iron-binding site in gastric cancer cells. 国際誌

    Masami Ijiri, Mikihiro Fujiya, Hiroaki Konishi, Hiroki Tanaka, Nobuhiro Ueno, Shin Kashima, Kentaro Moriichi, Junpei Sasajima, Katsuya Ikuta, Toshikatsu Okumura

    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine   39 ( 6 )   1010428317711311 - 1010428317711311   2017年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Ferrichrome is known to be a siderophore, but it was recently identified as a tumor-suppressive molecule derived from Lactobacillus casei ATCC334 ( L. casei). In the present study, we investigated the effects of ferrichrome in gastric cancer cells. Cell lines and xenograft models treated with ferrichrome demonstrated growth suppression. The expression levels of cleaved poly (adenosine diphosphate-ribose) polymerase, and cleaved caspase-9 were increased by ferrichrome treatment. Although the tumor-suppressive effects of ferrichrome were almost completely diminished by the iron chelation, the reduction in the intracellular iron by ferrichrome did not correlate with its tumor-suppressive effects. An exhaustive docking simulation indicated that iron-free ferrichrome can make stable conformations with various mammalian molecules, including transporters and receptors. In conclusion, probiotic-derived ferrichrome induced apoptosis in gastric cancer cells. The iron binding site of ferrichrome is the structure responsible for its tumor suppressive function.

    DOI: 10.1177/1010428317711311

    PubMed

    researchmap

  • Probiotic-derived ferrichrome inhibits colon cancer progression via JNK-mediated apoptosis. 国際誌

    Hiroaki Konishi, Mikihiro Fujiya, Hiroki Tanaka, Nobuhiro Ueno, Kentaro Moriichi, Junpei Sasajima, Katsuya Ikuta, Hiroaki Akutsu, Hiroki Tanabe, Yutaka Kohgo

    Nature communications   7   12365 - 12365   2016年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Previous reports have suggested that some probiotics inhibit tumorigenesis and cancer progression. However, the molecules involved have not yet been identified. Here, we show that the culture supernatant of Lactobacillus casei ATCC334 has a strong tumour-suppressive effect on colon cancer cells. Using mass spectrometry, we identify ferrichrome as a tumour-suppressive molecule produced by L. casei ATCC334. The tumour-suppressive effect of ferrichrome is greater than that of cisplatin and 5-fluorouracil, and ferrichrome has less of an effect on non-cancerous intestinal cells than either of those agents. A transcriptome analysis reveals that ferrichrome treatment induces apoptosis, which is mediated by the activation of c-jun N-terminal kinase (JNK). Western blotting indicates that the induction of apoptosis by ferrichrome is reduced by the inhibition of the JNK signalling pathway. This we demonstrate that probiotic-derived ferrichrome exerts a tumour-suppressive effect via the JNK signalling pathway.

    DOI: 10.1038/ncomms12365

    PubMed

    researchmap

  • microRNA-26a and -584 inhibit the colorectal cancer progression through inhibition of the binding of hnRNP A1-CDK6 mRNA. 国際誌

    Hiroaki Konishi, Mikihiro Fujiya, Nobuhiro Ueno, Kentaro Moriichi, Junpei Sasajima, Katsuya Ikuta, Hiroki Tanabe, Hiroki Tanaka, Yutaka Kohgo

    Biochemical and biophysical research communications   467 ( 4 )   847 - 52   2015年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    While the progress of chemotherapy and molecular targeted therapy has improved the outcome of colorectal cancer patients, the mortality of colon cancer remains high, indicating the need to develop novel therapeutic targets for improving the outcome of colon cancer. Heterogeneous ribonucleoprotein A1 (hnRNP A1) is highly expressed in colorectal cancer and its expression correlates with malignant transformation. In this study, we performed a microarray analysis with the RNA immunoprecipitation (RNA-IP) method and identified hnRNP A1-interacting miRs, including miR-26a and -584, in a colorectal cancer cell line, SW620. A SRB assay revealed the tumor suppressive effect of miR-26a and -584, and the tumor suppressive effect of these miRs was diminished by the downregulation of hnRNP A1. The combined method of a transcriptome analysis and RNA-IP revealed hnRNP A1-interacting mRNAs, including cyclin dependent kinase 6 (CDK6). A Western blot analysis revealed the downregulation of CDK6 in miR-26a and -584 overexpression cells, as well as hnRNP A1 knockdown cells. The binding assay indicated that the binding of hnRNP A1-CDK6 mRNA was reduced by transfection of miR-26a and -584. The expression of cleaved caspase-3 was induced in miR-26a and -584 overexpression cells. These data indicate that miR-26a and -584 inhibit the binding of hnRNP A1-CDK6 mRNA and induce colorectal cancer cell apoptosis.

    DOI: 10.1016/j.bbrc.2015.10.055

    PubMed

    researchmap

  • Probiotic-derived polyphosphate improves the intestinal barrier function through the caveolin-dependent endocytic pathway. 国際誌

    Kazuyuki Tanaka, Mikihiro Fujiya, Hiroaki Konishi, Nobuhiro Ueno, Shin Kashima, Junpei Sasajima, Kentaro Moriichi, Katsuya Ikuta, Hiroki Tanabe, Yutaka Kohgo

    Biochemical and biophysical research communications   467 ( 3 )   541 - 8   2015年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Probiotics exhibit beneficial functions for host homeostasis maintenance. We herein investigated the mechanism by which Lactobacillus brevis-derived poly P exhibited a beneficial function. Immunostaining indicated that poly P was captured in the plasma membrane via integrin β1 in Caco2/bbe cells. The uptake of poly P was reduced by the inhibition of integrin β1 as well as caveolin-1, a major component of lipid rafts. The function of poly P, including the induction of HSP27 and enhancement of the intestinal barrier function, was suppressed by the inhibition of caveolin-1, illustrating that the function of poly P was mediated by the endocytic pathway. High-throughput sequencing revealed that poly P induced tumor necrosis factor alpha-induced protein 3, which contributes to cytoprotection, including upregulation of the intestinal barrier function. The present study demonstrates a novel host-probiotic interaction through the uptake of bacterial substance into host cells, which is distinct from pattern recognition receptor pathways.

    DOI: 10.1016/j.bbrc.2015.09.159

    PubMed

    researchmap

  • Polyphosphate, an active molecule derived from probiotic Lactobacillus brevis, improves the fibrosis in murine colitis. 国際誌

    Shin Kashima, Mikihiro Fujiya, Hiroaki Konishi, Nobuhiro Ueno, Yuhei Inaba, Kentaro Moriichi, Hiroki Tanabe, Katsuya Ikuta, Takaaki Ohtake, Yutaka Kohgo

    Translational research : the journal of laboratory and clinical medicine   166 ( 2 )   163 - 75   2015年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Inflammatory bowel disease frequently causes intestinal obstruction because of extensive fibrosis. This study investigated whether polyphosphate (poly P), an active molecule derived from Lactobacillus brevis, could improve the fibrosis in a model of chronic colitis. In this study, dextran sodium sulfate (DSS)-induced chronic colitis models and trinitrobenzene sulfonic acid (TNBS)-induced colitis models were used as models of fibrosis. To clarify the mechanism responsible for the observed effects, Caco-2/brush border epithelial (BBE) and naive T helper lymphocyte (THP)-1 cells were treated with lipopolysaccharide (LPS) to induce inflammation. Non-cancer human colon fibroblast (CCD-18) cells were treated with transforming growth factor beta 1 (TGF-β1) to induce fibrosis. The expression levels of fibrosis- and inflammation-associated molecules were evaluated by both a Western blotting analysis and reverse transcriptase-polymerase chain reaction (RT-PCR). The histologic inflammation and fibrosis were significantly improved in the group administered poly P in both the DSS and TNBS colitis models. The levels of interleukin 1β (IL-1β) and tumor necrosis factor α (TNF-α) were significantly decreased by poly P treatment. The expression levels of TGF-β1 and collagens in the colitis mice were decreased by poly P. The LPS-induced expressions of IL-1β and TGF-β1 in Caco-2/BBE cells and of TNF-α in THP-1 cells were reduced by poly P treatment. Poly P did not affect the expression of collagens and connective tissue growth factor in the CCD-18 cells. In conclusion, poly P suppresses intestinal inflammation and fibrosis by downregulating the expression of inflammation- and fibrosis-associated molecules in the intestinal epithelium. The administration of poly P is therefore a novel option to treat fibrosis because of chronic intestinal inflammation.

    DOI: 10.1016/j.trsl.2015.02.002

    PubMed

    researchmap

  • Heterogeneous Nuclear Ribonucleoprotein A1 Improves the Intestinal Injury by Regulating Apoptosis Through Trefoil Factor 2 in Mice with Anti-CD3-induced Enteritis. 国際誌

    Katsuyoshi Ando, Mikihiro Fujiya, Hiroaki Konishi, Nobuhiro Ueno, Yuhei Inaba, Kentaro Moriichi, Katsuya Ikuta, Hiroki Tanabe, Takaaki Ohtake, Yutaka Kohgo

    Inflammatory bowel diseases   21 ( 7 )   1541 - 52   2015年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The role of hnRNP A1 in the onset of intestinal inflammation remains unclear. This study investigated the function of hnRNP A1 in mice enteritis models. METHODS: C57Bl6/J mice were intraperitoneally injected with anti-CD3 antibodies to develop enteritis. In the DSS-induced colitis group, the mice were allowed free access to 3% DSS solution in their drinking water for 5 days. 3H-mannitol flux and complementary DNA array tests were used to assess the intestinal barrier function and messenger RNA (mRNA) expression, respectively. Real-time PCR was performed after immunoprecipitation with anti-hnRNP antibodies to determine the specific mRNA binding of hnRNP A1. RESULTS: The hnRNP A1 expression was increased in the intestine of the mouse at 24 hours after treatment with anti-CD3 antibodies and 5 days after starting DSS administration. Small interfering RNA (siRNA) against hnRNP A1 exacerbated the intestinal injuries in both models. According to the microarray analysis, trefoil factor 2 (TFF2) was identified as a candidate molecule targeted by hnRNP A1 in the anti-CD3 antibody-induced enteritis group. Moreover, the binding between hnRNP A1 and TFF2 mRNA significantly increased in the enteritis mice, and the administration of siRNA against either hnRNP A1 or TFF2 exacerbated the degree of intestinal injury. In the DSS-induced colitis group, treatment with the siRNA of hnRNP A1 worsened the intestinal injury, while the expression of TFF3 did not change. CONCLUSIONS: hnRNP A1 improves intestinal injury in anti-CD3 antibody-induced enteritis mice through the upregulation of TFF2, which regulates apoptosis and enhances epithelial restoration, whereas this molecule ameliorates DSS-induced colitis through a different pathway.

    DOI: 10.1097/MIB.0000000000000401

    PubMed

    researchmap

  • Host-microbe interactions via membrane transport systems. 国際誌

    Hiroaki Konishi, Mikihiro Fujiya, Yutaka Kohgo

    Environmental microbiology   17 ( 4 )   931 - 7   2015年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Living organisms take in essential molecules and get rid of wastes effectively through the selective transport of materials. Especially in the digestive tract, advanced transport systems are indispensable for the absorption of nutrients and elimination of waste products. These transport pathways control physiological functions by modulating the ionic environment inside and outside the cells. Moreover, recent studies have shown the importance of the expression of trafficking-related molecules and the population of gut microbiota. We found that the molecules secreted from microorganisms are imported into the cells via transporters or endocytosis and that they activate cell survival pathways of intestinal epithelial cells. These findings indicate that the interactions between the gut microbiota and host cells are mediated, at least partly, by the membrane transport systems. In addition, it is well known that the breakdown of transport systems induces various diseases. This review highlights the significance of the transport systems as the pathogenic molecules and therapeutic targets in gastrointestinal disorders. For example, abnormal expression of the genes encoding membrane transport-related molecules is frequently involved in digestive diseases, such as colorectal cancer and inflammatory bowel disease. We herein review the significance of these molecules as pathogenic and therapeutic targets for digestive diseases.

    DOI: 10.1111/1462-2920.12632

    PubMed

    researchmap

  • microRNA-18a induces apoptosis in colon cancer cells via the autophagolysosomal degradation of oncogenic heterogeneous nuclear ribonucleoprotein A1. 国際誌

    M Fujiya, H Konishi, M K Mohamed Kamel, N Ueno, Y Inaba, K Moriichi, H Tanabe, K Ikuta, T Ohtake, Y Kohgo

    Oncogene   33 ( 40 )   4847 - 56   2014年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    It is well known that microRNAs (miRs) are abnormally expressed in various cancers and target the messenger RNAs (mRNAs) of cancer-associated genes. While (miRs) are abnormally expressed in various cancers, whether miRs directly target oncogenic proteins is unknown. The present study investigated the inhibitory effects of miR-18a on colon cancer progression, which was considered to be mediated through its direct binding and degradation of heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1). An MTT assay and xenograft model demonstrated that the transfection of miR-18a induced apoptosis in SW620 cells. A binding assay revealed direct binding between miR-18a and hnRNP A1 in the cytoplasm of SW620 cells, which inhibited the oncogenic functions of hnRNP A1. A competitor RNA, which included the complementary sequence of the region of the miR-18a-hnRNP A1 binding site, repressed the effects of miR-18a on the induction of cancer cell apoptosis. In vitro single and in vivo double isotope assays demonstrated that miR-18a induced the degradation of hnRNP A1. An immunocytochemical study of hnRNP A1 and LC3-II and the inhibition of autophagy by 3-methyladenine and ATG7, p62 and BAG3 siRNA showed that miR-18a and hnRNP A1 formed a complex that was degraded through the autophagolysosomal pathway. This is the first report showing a novel function of a miR in the autophagolysosomal degradation of an oncogenic protein resulting from the creation of a complex consisting of the miR and a RNA-binding protein, which suppressed cancer progression.

    DOI: 10.1038/onc.2013.429

    PubMed

    researchmap

  • MicroRNA-146b improves intestinal injury in mouse colitis by activating nuclear factor-κB and improving epithelial barrier function. 国際誌

    Toshie Nata, Mikihiro Fujiya, Nobohiro Ueno, Kentaro Moriichi, Hiroaki Konishi, Hiroki Tanabe, Takaaki Ohtake, Katsuya Ikuta, Yutaka Kohgo

    The journal of gene medicine   15 ( 6-7 )   249 - 60   2013年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The precise role of microRNAs in inflammatory disease is not clear. The present study investigated the effect of microRNA (miR-146b) with respect to improving intestinal inflammation. METHODS: The microRNA profile in interleukin-10 deficient mice was examined using microRNA arrays and miR-146b was selected for the subsequent experiments. The expression vectors containing either the whole sequence of miR-146b or small interfering RNA for miR-146b were intraperitoneally administered to the dextran sodium sulfate (DSS)-induced colitis mouse. The expression levels of inflammation-related mediators were examined by the reverse transcriptase-polymerase chain reaction and western blotting analysis. Intestinal barrier function was evaluated by an ex vivo mannitol flux study. RESULTS: The overexpression of miR-146b activated the NF-κB pathway, improved epithelial barrier function, relieved intestinal inflammation in the DSS-induced colitis mice, and improved the survival rate of mice with lethal colitis. Furthermore, this amelioration of intestinal inflammation by miR-146b was negated by the inhibitor for the NF-κB pathway. The overexpression of miR-146b decreased the expression of siah2, which has a target sequence for miR-146b, and promoted the ubiquitination of TRAF proteins. This suggests that the up-regulation of NF-κB by miR-146b was mediated by inhibition of the ubiquitination of TRAF proteins upstream of NF-κB. CONCLUSIONS: miR-146b improves intestinal inflammation by up-regulating NF-κB as a result of the decreased expression of siah2, which ubiquitinates TRAF proteins. Modulation of the miR-146b expression is a potentially useful therapy for the treatment of intestinal inflammation via activation of the NF-κB pathway.

    DOI: 10.1002/jgm.2717

    PubMed

    researchmap

  • Traffic control of bacteria-derived molecules: a new system of host-bacterial crosstalk. 国際誌

    Hiroaki Konishi, Mikihiro Fujiya, Yutaka Kohgo

    International journal of cell biology   2013   757148 - 757148   2013年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Virulent microorganisms, such as pathogenic bacteria and viruses, are recognized by pattern recognition receptors (PRRs), including toll-like receptors (TLRs) and nucleotide-binding oligomerization-domain proteins (NODs), and induce inflammatory responses in mammalian hosts. Conversely, commensal bacteria and probiotics, which symbiotically confer health benefits on the host organisms, can lodge in the host intestinal tract without inducing intestinal inflammation. Recent advances in investigations concerning host-microbial interactions have shown that some effector molecules secreted from beneficial bacteria activate cell survival pathways, such as those mediated by p38 MAPK and Akt, and bring health benefits to mammalian hosts. It is noteworthy that such bacteria-derived molecules are taken into the intestinal epithelia through a transport or endocytosis system, thereafter exhibiting their beneficial effects. Understanding this traffic control process can aid in the comprehension of host and microbe interactions and may provide new insight to clarify the pathogenesis of intestinal disorders. This paper highlights the intestinal trafficking systems of bacteria-derived molecules that affect the bacterial functions and modulate epithelial signaling cascades. The latter mechanism may contribute to the maintenance of intestinal homeostasis by improving the host damage induced by virulence factors and various disease states.

    DOI: 10.1155/2013/757148

    PubMed

    researchmap

  • Probiotic-derived polyphosphate enhances the epithelial barrier function and maintains intestinal homeostasis through integrin-p38 MAPK pathway. 国際誌

    Shuichi Segawa, Mikihiro Fujiya, Hiroaki Konishi, Nobuhiro Ueno, Naoyuki Kobayashi, Tatsuro Shigyo, Yutaka Kohgo

    PloS one   6 ( 8 )   e23278   2011年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Probiotics exhibit beneficial effects on human health, particularly in the maintenance of intestinal homeostasis in a complex manner notwithstanding the diversity of an intestinal flora between individuals. Thus, it is highly probable that some common molecules secreted by probiotic and/or commensal bacteria contribute to the maintenance of intestinal homeostasis and protect the intestinal epithelium from injurious stimuli. To address this question, we aimed to isolate the cytoprotective compound from a lactobacillus strain, Lactobacillus brevis SBC8803 which possess the ability to induce cytoprotective heat shock proteins in mouse small intestine. L. brevis was incubated in MRS broth and the supernatant was passed through with a 0.2-µm filter. Caco2/bbe cells were treated with the culture supernatant, and HSP27 expression was evaluated by Western blotting. HSP27-inducible components were separated by ammonium sulfate precipitation, DEAE anion exchange chromatography, gel filtration, and HPLC. Finally, we identified that the HSP27-inducible fraction was polyphosphate (poly P), a simple repeated structure of phosphates, which is a common product of lactobacilli and other bacteria associated with intestinal microflora without any definitive physiological functions. Then, poly P was synthesized by poly P-synthesizing enzyme polyphosphate kinase. The synthesized poly P significantly induced HSP27 from Caco2/BBE cells. In addition, Poly P suppressed the oxidant-induced intestinal permeability in the mouse small intestine and pharmacological inhibitors of p38 MAPK and integrins counteract its protective effect. Daily intrarectal administration of poly P (10 µg) improved the inflammation grade and survival rate in 4% sodium dextran sulfate-administered mice. This study, for the first time, demonstrated that poly P is the molecule responsible for maintaining intestinal barrier actions which are mediated through the intestinal integrin β1-p38 MAPK.

    DOI: 10.1371/journal.pone.0023278

    PubMed

    researchmap

▼全件表示

MISC

  • PROBIOTIC-DERIVED POLYPHOSPHATE IMPROVES DAMAGED INTESTINAL EPITHELIA THROUGH INDUCING PLATELET-DERIVED CELL GROWTH MOLECULES

    Shotaro Isozaki, Mikihiro Fujiya, Hiroaki Konishi, Hiroki Tanaka, Yuuki Murakami, Yuya Sugiyama, Yu Kobayashi, Takahiro Sasaki, Takehito Kunogi, Keitaro Takahashi, Kazuyuki Tanaka, Aki Sakatani, Katsuyoshi Ando, Nobuhiro Ueno, Shin Kashima, Takuma Goto, Shuhei Takauji, Kentaro Moriichi, Hiroki Tanabe, Yusuke Mizukami, Toshikatsu Okumura

    GASTROENTEROLOGY   158 ( 6 )   S501 - S501   2020年5月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:W B SAUNDERS CO-ELSEVIER INC  

    0

    Web of Science

    researchmap

  • ABNORMAL ACTIVATION OF HNRNPA0 INHIBITS CANCER CELL APOPTOSIS AND PROMOTES EXCESSIVE MITOSIS IN CANCER CELLS

    Hiroaki Konishi, Mikihiro Fujiya, Akemi Kita, Hiroki Tanaka, Shin Kashima, Aki Sakatani, Tatsuya Dokoshi, Katsuyoshi Ando, Nobuhiro Ueno, Kentaro Moriichi, Takuya Iwama, Keitaro Takahashi, Yuuki Murakami, Katsuya Ikuta, Yusuke Mizukami, Takuma Goto, Toshikatsu Okumura

    GASTROENTEROLOGY   156 ( 6 )   S484 - S484   2019年5月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:W B SAUNDERS CO-ELSEVIER INC  

    0

    Web of Science

    researchmap

産業財産権

  • 血小板凝集剤

     詳細を見る

    出願人:旭川医科大学

    出願番号:特願2020-001319  出願日:2021年1月

    researchmap

  • ペプチド系抗腫瘍薬の創製

    市川 聡, 小嶋 啓太, 藤谷 幹浩, 小西 弘晃

     詳細を見る

    出願人:国立大学法人北海道大学, 国立大学法人旭川医科大学

    出願番号:JP2019003482  出願日:2019年1月

    公表番号:WO2019-151439  公表日:2019年8月

    J-GLOBAL

    researchmap

  • ペプチド系抗腫瘍薬の創製

    市川 聡, 小嶋 啓太, 藤谷 幹浩, 小西 弘晃

     詳細を見る

    出願人:国立大学法人北海道大学, 国立大学法人旭川医科大学

    出願番号:JP2019003482  出願日:2019年1月

    特許番号/登録番号:特許第7201181号  登録日:2022年12月 

    J-GLOBAL

    researchmap

  • 抗腫瘍剤

    藤谷 幹浩, 小西 弘晃, 盛一 健太郎

     詳細を見る

    出願人:国立大学法人旭川医科大学

    出願番号:JP2017001803  出願日:2017年1月

    公表番号:WO2017-126626  公表日:2017年7月

    J-GLOBAL

    researchmap

  • 抗腫瘍剤

    藤谷 幹浩, 小西 弘晃, 盛一 健太郎

     詳細を見る

    出願人:国立大学法人旭川医科大学

    出願番号:特願2017-562903  出願日:2017年1月

    特許番号/登録番号:特許第6830255号  登録日:2021年1月 

    J-GLOBAL

    researchmap

受賞

  • Digestive Disease Week 2014 Poster of Distinction

    2014年5月   AGA  

     詳細を見る

共同研究・競争的資金等の研究課題

  • 炎症性腸疾患におけるCircular RNA-RNA結合蛋白相互作用の解析

    研究課題/領域番号:24K11079  2024年4月 - 2027年3月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    安藤 勝祥, 高橋 賢治, 小西 弘晃, 藤谷 幹浩

      詳細を見る

    配分額:4,550,000円 ( 直接経費:3,500,000円 、 間接経費:1,050,000円 )

    researchmap

  • 有益菌由来活性分子を用いた新規バレット食道癌予防・治療法開発の基盤研究

    研究課題/領域番号:22K08047  2022年4月 - 2026年3月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    盛一 健太郎, 小西 弘晃, 藤谷 幹浩

      詳細を見る

    配分額:4,160,000円 ( 直接経費:3,200,000円 、 間接経費:960,000円 )

    当教室で保有する24株(菌株の通し番号を#2~#25とする)の有益菌を至適条件で培養したのちに,培養上清を回収した.回収した培養上清を希釈してOE19,OE33,KYSE30,KYSE70,Het-1Aに添加して,細胞増殖能の変化についてSRB assayで検討した.また,同様に培養上清を希釈したのちOE19,OE33,KYSE30,KYSE70に添加してSOX2,TP63,CDX2,MUC2,SOX9,KRT8,KRT18,CDH1,TGFB1のmRNAの発現をreal-time PCRで評価(Het-1Aは除く)した.SRB assayの結果は#2の添加によりOE33は90%以上,OE19は80%以上,KYSE70は約70%,KYSE30は約60%の増殖抑制効果を認めたが,正常食道扁平上皮株であるHet-1Aでは約30%の増殖抑制効果にとどまった.その他の培養上清でも,増殖抑制効果を認めるものを複数認めたが,最大でも約30%程度であり,増殖抑制効果については上清#2が最も高かった.real-time PCRによる上記mRNA発現の検討ではSRB assayと同様に希釈した培養上清を添加して,コントロールと比較して10倍または1/10以上変化があった上清は,#2,6,8,12,16,17,19,20,23,25であった.同様にOE19では,#2,4-7,14,22,23,24,25,KYSE30では,#2,17,20,23,25,KYSE70では,#2,5,14,20,24,25であった.

    researchmap

  • 有益微生物由来分子を用いた小児白血病治療薬の開発の基盤研究

    研究課題/領域番号:22K15363  2022年4月 - 2025年3月

    日本学術振興会  科学研究費助成事業  若手研究

    小西 弘晃

      詳細を見る

    配分額:4,680,000円 ( 直接経費:3,600,000円 、 間接経費:1,080,000円 )

    乳酸菌やビフィズス菌などのプロバイオティクスはヨーグルトなどの発酵食品に含まれるヒトに有益な作用をもたらす微生物である。私はプロバイオティクス由来抗腫瘍分子のスクリーニングを実施することにより、乳酸菌由来Ferrichromeや麹菌由来Heptelidic acidが非腫瘍細胞には低毒性かつ消化器癌細胞に対して強い抗腫瘍作用を発揮することを突き止めた。さらに、予備的検討からプロバイオティクス由来抗腫瘍分子を癌治療に応用するためには癌腫の性質に合わせた抗腫瘍分子のスクリーニングが必要であることを見出した。本研究では、希少がんであるため新薬開発が遅く、また、治癒後の長期生存が望めることから高い安全性が求められる小児白血病を対象にプロバイオティクス由来抗腫瘍分子を作用させその抗腫瘍効果を検証した。麹菌の培養上清より同定したHeptelidic acidは小児B細胞性およびT細胞性急性白血病モデル細胞において強い増殖抑制作用を発揮した。また、Heptelidic acidを処置した白血病細胞ではプログラム細胞死が誘導されていた。Heptelidic acidの持つ抗腫瘍作用は既存抗癌剤であるビンクリスチンやドキソルビシンと相加・相乗的に作用した。in vivo細胞株移植モデルおよび患者細胞移植モデルにおいてHeptelidic acidは重篤な有害事象を引き起こすことなく抗腫瘍効果を発揮した。

    researchmap

  • プロバイオティクス由来抗腫瘍活性物質を応用した新規小児がん治療薬開発の基盤研究

    研究課題/領域番号:21KK0291  2022年 - 2024年

    日本学術振興会  科学研究費助成事業  国際共同研究加速基金(国際共同研究強化(A))

    小西 弘晃

      詳細を見る

    配分額:15,600,000円 ( 直接経費:12,000,000円 、 間接経費:3,600,000円 )

    プロバイオティクスは適正量を摂取した際に宿主に有益な作用をもたらす微生物群の総称であり、特定のプロバイオティクスが消化器癌や乳癌など多様な癌腫に対して優れた抗腫瘍活性を発揮することが数多く報告されている。本研究においては私が麹菌の培養上清より同定したHeptelidic acidが小児がんに対して抗腫瘍効果を発揮するかを検討した。これまでにHeptelidic acidは小児B細胞性急性白血病細胞を用いたin vitroモデル、患者由来細胞を用いたex vivoモデル、及びin vivo Patient derived xenograft (PDX)モデルにおいて優れた抗腫瘍効果を発揮することを確認した。また、Heptelidic acidによる抗腫瘍効果は既存抗癌剤であるビンクリスチンと相乗的に作用することを明らかにした。PDXモデルにおいて、重篤な有害事象は確認されないにもかかわらず抗腫瘍効果が確認されたことから、Heptelidic acidは効果のみならず安全性に優れた治療薬候補であることを実証した。Heptelidic acidによる抗腫瘍作用は解糖系関連酵素の阻害によるATPの枯渇によりもたらされていることを明らかにした。このほかにもHeptelidic acidは小児T細胞性急性白血病細胞や神経膠芽腫、小児脳腫瘍をはじめとする多数の小児がん細胞に対して抗腫瘍効果を発揮しうることを見出した。

    researchmap

  • 腸管外疾患治療に有効な有益菌由来分子の同定と作用機序解明に基づく新薬開発基盤研究

    研究課題/領域番号:21K07929  2021年4月 - 2024年3月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    藤谷 幹浩, 嘉島 伸, 小西 弘晃, 澤田 康司

      詳細を見る

    配分額:4,160,000円 ( 直接経費:3,200,000円 、 間接経費:960,000円 )

    (1)遠隔臓器の疾患に有効なプロバイオティクス由来活性分子の同定
    2021年度はLactobacillus brevisの死菌による肝細胞の脂肪酸蓄積減少効果を証明し、この作用は腸管上皮から分泌される何らかの活性分子を介して発揮される可能性を示した。2022年度は、乳酸酸性菌由来分子による皮膚障害改善効果について検討した。腸管上皮細胞を上段に、ヒト表皮由来HacaT細胞あるいはマクロファージ様分化THP-1細胞を下段に培養したトランスウェルを作製した。このトランスウェルの上段に乳酸酸性菌由来分子Aを添加し、下段に炎症惹起分子を添加して、HacaT細胞およびマクロファージ様分化THP-1細胞の炎症関連分子発現を検討した。その結果、乳酸酸性菌由来分子A投与により、HacaT細胞およびマクロファージ様分化THP-1細胞の炎症関連分子発現が有意に減少した。また、上段に腸管上皮細胞を培養しなかった場合には、この効果は認められなかった。
    (2)プロバイオティクス由来分子の標的腸管細胞への作用、遠隔臓器の障害改善機序
    2021年度は高脂肪餌マウスモデルにてLactobacillus brevis死菌由来分子の経口投与が、肝細胞におけるインスリン感受性を変化させ、脂肪沈着を減少させる可能性を示した。2022年度は、乳酸酸性菌由来分子Aによる皮膚障害改善作用をin vivoで検討した。hapten 2,4 dinitrofluorobenzene (DNFB)をマウス皮膚に塗布しハプテン誘導皮膚障害マウスモデルを作成した。乳酸酸性菌由来分子Aを経口投与した結果、皮膚の肉眼的、組織学的障害は有意に改善した。また、皮膚における炎症関連分子の発現も有意に減少した。(1)の結果も含め、乳酸酸性菌由来分子Aによる皮膚障害改善効果は腸管上皮からのセカンドメッセンジャーを介して発揮される可能性が示唆された。

    researchmap

  • 細菌由来の分子による腸ー肺連関メカニズムに基づいたARDS治療薬開発の基盤研究

    研究課題/領域番号:21K09038  2021年4月 - 2024年3月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    高氏 修平, 上野 伸展, 小西 弘晃, 藤谷 幹浩

      詳細を見る

    配分額:4,290,000円 ( 直接経費:3,300,000円 、 間接経費:990,000円 )

    本研究では1.細菌由来の分泌物からARDSモデルにおける肺の炎症を改善する菌由来分子を同定すること.2.菌由来分子による腸および肺内細菌叢の変化を明らか にすること.3.菌由来分子により誘導される腸管上皮あるいはリンパ球・単球由来の分子の中からARDSを改善させる作用を仲介する分子を同定すること,これら を通して腸ー肺連関のメカニズムを明らかにすることを目指している.
    本年度は,前年に引き続いて細菌由来の分泌物から肺の炎症抑制分子の探索を目標として下記の通り実験を進めた.
    本年度よりヒト腸管上皮細胞(HCEC-1CT),ヒト微小肺内上皮細胞(Human Pulmonary Microvascular Endothelial Cell, HPMEC)の共培養系を使用した.
    各種プロバイオティクスの培養上清を上記細胞に投与した後に,lipopolysaccharide(LPS)で活性化させ,24時 間後に上記細胞からRNAを抽出,その後,RT-PCRにより各種炎症性サイトカイン(IL-1β,TNF-α,IL-6)の発現量変化を観察した.
    しかしながら,HPMECのLPS刺激前後でサイトカインの有意な変化は認めなかった.今後はLPSの種類などを変えて,同様の実験を行いヒト細胞での実験系の確立を目指す.最終的に肺の炎症を抑制する作用を有するプロバイオティクス上清について種々のカラムを用いて分離していく.

    researchmap

  • プロバイオティクス由来抗腫瘍活性物質を応用した新規膵癌治療薬開発の基盤研究

    研究課題/領域番号:19K16484  2019年4月 - 2023年3月

    日本学術振興会  科学研究費助成事業  若手研究

    小西 弘晃

      詳細を見る

    配分額:4,160,000円 ( 直接経費:3,200,000円 、 間接経費:960,000円 )

    私はプロバイオティクスの培養上清を膵癌細胞に処置し、麹菌の培養液に強い抗癌作用があることを明らかにした。この培養上清をHPLCにより分画化し、質量分析解析及びNMR解析によりその作用を仲介する分子がHeptelidic acid(HA)であることを明らかにした。HAは膵癌細胞に対して細胞周期の異常および細胞死の誘導を引き起こすことで抗腫瘍効果を発揮していることを明らかにした。また、HAは消化管を透過し遠隔臓器に直接的に作用することで抗腫瘍効果を発揮しうることを実証した。本研究により、プロバイオティクスが多種多様な癌に対して作用を発揮しうること及びその作用メカニズムの一端を明らかにした。

    researchmap

  • 有益菌由来活性分子の同定と分子特異的作用機序の解明による新規治療薬開発の基盤研究

    研究課題/領域番号:18K07927  2018年4月 - 2022年3月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    藤谷 幹浩, 上野 伸展, 小西 弘晃, 盛一 健太郎

      詳細を見る

    配分額:4,420,000円 ( 直接経費:3,400,000円 、 間接経費:1,020,000円 )

    Aspergillus oryzaeの培養上清から抗膵癌分子heptelidic acidを同定した。この分子はp38 MAPK経路を介して細胞死を誘導した。また、マウス摘出小腸を用いた検討にてheptelidic acidが腸管を通過して膵へ到達し、抗腫瘍作用を発揮することが示唆された。heptelidic acidはGAPDH活性阻害によりメラノーマに対しても抗腫瘍効果を発揮した。Lactobacillus brevis由来ポリリン酸は腸管障害部位に血小板集簇させ創傷治癒を促進させた。また、Lactobacillus casei由来フェリクロームはp53活性化を介して抗膵癌作用を発揮した。

    researchmap

  • 腸内細菌由来抗腫瘍活性物質の同定とその認識機構および細胞シグナル活性化機構の解明

    研究課題/領域番号:16H06607  2016年8月 - 2018年3月

    日本学術振興会  科学研究費助成事業  研究活動スタート支援

    小西 弘晃

      詳細を見る

    配分額:2,990,000円 ( 直接経費:2,300,000円 、 間接経費:690,000円 )

    腸内細菌の培養上清の中で最も強い癌細胞の増殖抑制効果を発揮したL.casei ATCC334の培養上清を繰り返し分離し、抗腫瘍活性物質フェリクロームを同定した。フェリクロームの抗腫瘍効果は5-FUやシスプラチンの効果を上回り、これらと併用することで相加効果が認められた。フェリクロームは小胞体ストレス経路を活性化させ抗腫瘍効果を発揮した。フェリクロームの立体構造に基づいた分子シミュレーションによりフェリクローム認識分子群を見出した。癌モデルマウスにフェリクロームを投与すると腫瘍増殖の抑制効果が発揮され、薬効が認められた10倍量を連日投与しても死亡個体はなく、血液検査値にも変化を及ぼさなかった。

    researchmap

▼全件表示